"This specially designed healing environment has been created to extend an exceptional, supportive experience to our patients and their families. Henry Ford Allegiance Medical Oncology offers technologically advanced care in a healing environment, which includes calming decorative art, increased natural lighting and soft music to soothe both patients and their families who are facing a stressful and vulnerable time."

During the past decade, Center for Hematology/Oncology of S. Michigan conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Hematology/Oncology of S. Michigan" #1 collaborator was "Walther Cancer Institute" with 4 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Center for Hematology/Oncology of S. Michigan" are "Head and Neck Cancer" (1 trials), "Metastatic Breast Cancer" (1 trials), "Myelodysplastic Syndromes" (1 trials) and "Prostate Cancer" (1 trials). Many other conditions were trialed in "Center for Hematology/Oncology of S. Michigan" in a lesser frequency.

Most popular intervention types in "Center for Hematology/Oncology of S. Michigan" are "Drug" (4 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "Azacitidine" (1 trials), "Azacitidine (Monotherapy)" (1 trials), "Docetaxel" (1 trials) and "Erythropoietin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Center for Hematology/Oncology of S. Michigan" are 2 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Center for Hematology/Oncology of S. Michigan". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Center for Hematology/Oncology of S. Michigan, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Hematology/Oncology of S. Michigan, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".